| 1 min read
Register for free to listen to this article
Listen with Speechify
0:00
1:00
SANTA BARBARA, Calif.—Despite the popularity of methods relying on fluorescent proteins like GFP, the development of these techniques is being hampered by the low quantum yield and rapid photobleaching properties of many of these proteins. Researchers at University of California, Santa Barbara and Pasadena's Caltech are trying to change this, however.
 
As reported in Nature Biotechnology, the scientists used structure-guided design and fluorescence activated cell sorting to create and identify improved versions of blue fluorescent protein (BFP). Of the 330,000 unique sequences they generated, the researchers isolated 20 colonies for further characterization. They found that many of the clones carried mutation known to improve brightness in other fluorescent proteins, but they also identified novel mutations.
 
They then selected two clones with particularly enhanced brightness and found that one, which they named Azurite, had a significantly higher quantum yield than the parental BFP. And when they expressed Azurite in mammalian cells at 37°C, they noted its photobleaching half-life improved 40-fold over BFP, making it particularly well suited for a variety of fluorescence-based screening methods.
 

About the Author

Related Topics

Loading Next Article...
Loading Next Article...
Subscribe to Newsletter

Subscribe to our eNewsletters

Stay connected with all of the latest from Drug Discovery News.

Subscribe

Sponsored

Clear sample tubes are shown in a clear tote with red lids in a sample prep robot with a blue and silver industrial lab background.

The crucial role of sample preparation in biotherapy manufacturing

Discover how better sample preparation can unlock improved assay accuracy and analytical results.
A black mosquito is shown on pink human skin against a blurred green backdrop.

Discovering deeper insights into malaria research

Malaria continues to drive urgent research worldwide, with new therapies and tools emerging to combat the parasite’s complex lifecycle and global burden.
Three burgundy round and linear conformations of oligonucleotides are shown against a black background.

Accelerating RNA therapeutic testing with liver microphysiological platforms

Researchers can now study oligonucleotide delivery and efficacy in a system that models a real human liver.
Drug Discovery News March 2025 Issue
Latest IssueVolume 21 • Issue 1 • March 2025

March 2025

March 2025 Issue

Explore this issue